A major focus of my research career has centered on the design, analysis and coordination of clinical trials. Over the past ten years I have overseen data coordinating and biostatistical efforts for numerous studies including trials evaluating a computer-assisted screening and brief intervention to reduce alcohol use in Latino drinkers, determining the efficacy of a novel integrated tobacco order set embedded within the EMR to promote sustained smoking abstinence in hospitalized smokers, and examining pharmaceutical and behavioral interventions in children and adults with autism spectrum and Tourette disorders through the Research Unit on Pediatric Psychopharmacology (RUPP) Autism network and the Behavioral Sciences Consortium for Tourette Syndrome. I served as the PI of the data coordinating center for the RUPP Autism Network study of Guanfacine for the treatment of hyperactivity. I am currently the Director of the Data Coordinating Center for the multicenter Autism Biomarkers for Clinical Trials (ABC-CT) study. I'm also a senior statistician for the PCORI funded Strategies to Reduce Injuries and Develop confidence in Elders (STRIDE) trial, a cluster randomized trial of 6000 participants from 80 primary care practices.
Another area of research concentration is the epidemiology and treatment of metabolic disorders such as obesity and diabetes. My dissertation focused on the effects of physical activity on body weight maintenance and diabetes in older individuals. More recent contributions have examined metabolic consequences of obesity in children and behavioral approaches to weight reduction. I've also studied mechanisms of insulin resistance in children and adults.
Clinical Trials as Topic; Data Collection; Diabetes Mellitus; Emergency Medicine; Epidemiology; Nutritional and Metabolic Diseases; Obesity; Statistics as Topic
Conditions | Study Title |
---|---|
Mental Health & Behavioral Research | Ketamine for Adolescent Suicidality |
Children's Health; Diseases of the Digestive System - Liver | The Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis |